{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:31:44Z","timestamp":1778837504750,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1106","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>A cohort of high dose-rate (HDR) monotherapy patients was analyzed to (i) establish the frequency of non-malignant urethral stricture; (ii) explore the relation between stricture formation with the dose distribution along the length of the urethra, and MRI radiomics features of the prostate gland.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>A retrospective review of treatment records of patients who received 19\u2009Gy single fraction of HDR brachytherapy (BT) was carried out. A matched pair analysis used one control for each stricture case matched with pre-treatment International Prostate Symptom Score (IPSS) score, number of needles used and clinical target volume volume for each stricture case identified.<\/jats:p>\n                  <jats:p>For all data sets, pre-treatment T \u00a02 weighted MRI images were used to define regions of interests along the urethra and within the whole prostate gland. MRI textural radiomics features\u2014energy, contrast and homogeneity were selected. Wilcoxon signed-rank test was performed to investigate significant differences in dosimetric parameters and MRI radiomics feature values between cases and controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>From Nov 2010 to July 2017, there were 178 patients treated with HDR BT delivering 19\u2009Gy in a single dose. With a median follow-up of 28.2 months, a total of 5\/178 (3%) strictures were identified.<\/jats:p>\n                  <jats:p>10 patients were included in the matched pair analysis. The urethral dosimetric parameters investigated were not statistically different between cases and controls (p &amp;gt; 0.05). With regards to MRI radiomics feature analysis, significant differences were found in contrast and homogeneity between cases and controls (p &amp;lt; 0.05). However, this did not apply to the energy feature (p = 0.28).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>In this matched pair analysis, no association between post-treatment stricture and urethral dosimetry was identified. Our study generated a preliminary clinical hypothesis suggesting that the MRI radiomics features of homogeneity and contrast of the prostate gland can potentially identify patients who develop strictures after HDR BT. Although the sample size is small, this warrants further validation in a larger patient cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>Urethral stricture has been reported as a specific late effect with prostate HDR brachytherapy. Our study reported a relatively low stricture rate of 3% and no association between post-treatment stricture and urethral dosimetry was identified. MRI radiomics features can potentially identify patients who are more prone to develop strictures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20190760","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:36:52Z","timestamp":1574966212000},"source":"Crossref","is-referenced-by-count":9,"title":["A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer"],"prefix":"10.1093","volume":"93","author":[{"given":"Yat Man","family":"Tsang","sequence":"first","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Vignarajah","sequence":"additional","affiliation":[{"name":"Sunshine Coast University Hospital , Queensland , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Mcwilliam","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester , Manchester , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Tharmalingam","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry","family":"Lowe","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester , Manchester , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood , United Kingdom"},{"name":"Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester , Manchester , United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"2024050215253055400_b1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ijrobp.2010.09.006","article-title":"High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial","volume":"82","author":"Barkati","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","volume":"126","author":"Strouthos","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.brachy.2015.01.004","article-title":"High-dose-rate brachytherapy as a monotherapy for prostate cancer\u2014Single-institution results of the extreme fractionation regimen","volume":"14","author":"Kukie\u0142ka","year":"2015","journal-title":"Brachytherapy"},{"key":"2024050215253055400_b4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-Dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b10","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.brachy.2017.04.018","article-title":"Prostate HDR monotherapy: initial efficacy results from a randomized trial of one versus two fractions","volume":"16","author":"Morton","year":"2017","journal-title":"Brachytherapy"},{"key":"2024050215253055400_b11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","article-title":"Urethral stricture following high dose rate brachytherapy for prostate cancer","volume":"91","author":"Sullivan","year":"2009","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b12","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ijrobp.2018.08.015","article-title":"A systematic Post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy","volume":"102","author":"Olsson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.radonc.2014.10.007","article-title":"Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer","volume":"113","author":"D\u00edez","year":"2014","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"The Lancet"},{"key":"2024050215253055400_b15","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"2024050215253055400_b16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"2024050215253055400_b17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/tcr.2016.06.20","article-title":"Prostate cancer radiomics and the promise of radiogenomics","volume":"5","author":"Stoyanova","year":"2016","journal-title":"Transl Cancer Res"},{"key":"2024050215253055400_b18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1148\/radiol.13122697","article-title":"Quantitative imaging in cancer evolution and ecology","volume":"269","author":"Gatenby","year":"2013","journal-title":"Radiology"},{"key":"2024050215253055400_b19","doi-asserted-by":"crossref","DOI":"10.1186\/s12880-015-0069-9","article-title":"Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models","volume":"15","author":"Khalvati","year":"2015","journal-title":"BMC Med Imaging"},{"key":"2024050215253055400_b20","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1118\/1.4918318","article-title":"Automated prostate cancer detection using T 2-weighted and high- b -value diffusion-weighted magnetic resonance imaging","volume":"42","author":"Kwak","year":"2015","journal-title":"Med Phys"},{"key":"2024050215253055400_b21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmri.25335","article-title":"Haralick textural features on T \u00a02 -weighted MRI are associated with biochemical recurrence following radiotherapy for peripheral zone prostate cancer","volume":"45","author":"Gnep","year":"2017","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"2024050215253055400_b22","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1088\/0031-9155\/60\/7\/2685","article-title":"Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness","volume":"60","author":"Vignati","year":"2015","journal-title":"Phys Med Biol"},{"key":"2024050215253055400_b23","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1007\/s00330-015-3701-8","article-title":"Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores","volume":"25","author":"Wibmer","year":"2015","journal-title":"Eur Radiol"},{"key":"2024050215253055400_b24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijrobp.2007.12.026","article-title":"A phase II study of High-Dose-Rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer","volume":"72","author":"Corner","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiotherapy and Oncology"},{"key":"2024050215253055400_b26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"2024050215253055400_b27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2010.10.009","article-title":"Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer","volume":"82","author":"Mohammed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brachy.2012.03.004","article-title":"Urethral strictures following high-dose-rate brachytherapy for prostate cancer: analysis of risk factors","volume":"12","author":"Hindson","year":"2013","journal-title":"Brachytherapy"},{"key":"2024050215253055400_b29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050215253055400_b30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/09553002.2018.1492756","article-title":"Rectal wall MRI radiomics in prostate cancer patients: prediction of and correlation with early rectal toxicity","volume":"94","author":"Abdollahi","year":"2018","journal-title":"Int J Radiat Biol"},{"key":"2024050215253055400_b31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.radonc.2018.10.027","article-title":"Vulnerabilities of radiomic signature development: the need for safeguards","volume":"130","author":"Welch","year":"2019","journal-title":"Radiotherapy and Oncology"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/93\/1106\/20190760\/57376359\/bjr.20190760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/93\/1106\/20190760\/57376359\/bjr.20190760.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T16:50:02Z","timestamp":1714668602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20190760\/7492607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":31,"journal-issue":{"issue":"1106","published-online":{"date-parts":[[2019,12,2]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20190760","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,12,2]]},"article-number":"20190760"}}